Page 77 - AN-2-1

Advanced Neurology Alpha-synuclein, depression and neurodegeneration

symptomatology in a mouse model of alpha-synuclein 56. Han Z, Tian R, Ren P, et al., 2018, Parkinson’s disease and
pathology. Neurobiol Aging, 83: 11–20. Alzheimer’s disease: A Mendelian randomization study.
BMC Med Genet, 19: 215.
https://doi.org/10.1016/j.neurobiolaging.2019.08.007
https://doi.org/10.1186/s12881-018-0721-7
45. Ishiguro M, Baba H, Maeshima H, et al., 2019, Increased
serum levels of α-synuclein in patients with major depressive 57. Talwar P, Gupta R, Kushwaha S, et al., 2019, Viral induced
disorder. Am J Geriatr Psychiatry, 27: 280–286. oxidative and inflammatory response in Alzheimer’s
disease pathogenesis with identification of potential drug
https://doi.org/10.1016/j.jagp.2018.10.015
candidates: A systematic review using systems biology
46. Rotter A, Lenz B, Pitsch R, et al., 2019, Alpha-synuclein approach. Curr Neuropharmacol, 17: 352–365.
RNA expression is increased in major depression. Int J Mol
Sci, 20: 2029. https://doi.org/10.2174/1570159x16666180419124508
58. Fransquet PD, Lacaze P, Saffery R, et al., 2020, DNA
https://doi.org/10.3390/ijms20082029
methylation analysis of candidate genes associated with
47. Fieling H, Gozner A, Romer KD, et al., 2008, Alpha-synuclein dementia in peripheral blood. Epigenomics, 12: 2109–2123.
mRNA levels correspond to Beck Depression Inventory
scores in females with eating disorders. Neuropsychobiology, https://doi.org/10.2217/epi-2020-0236
58: 48–52. 59. Gibbons A, McPherson K, Gogos A, Dean B, 2021, An
investigation into nicotinic receptor involvement in mood
https://doi.org/10.1159/000155991
disorders uncovers novel depression candidate genes.
48. Bruno D, Plaska CR, Clark DP, et al., 2021, CSF α-synuclein J Affect Disord, 288: 154–160.
correlates with CSF neurogranin in late-life depression. Int J
Neurosci, 131: 357–361. https://doi.org/10.1016/j.jad.2021.04.007
60. Rajeevan H, Osier MV, Cheung KH, et al., 2003, ALFRED:
https://doi.org/10.1080/00207454.2020.1744596 The ALlele FREquency database. Update. Nucleic Acids Res,
49. Eyre HA, Eskin A, Nelson SF, et al., 2016, Genomic predictors 31: 270–271.
of remission to antidepressant treatment in geriatric https://doi.org/10.1093/nar/gkg043
depression using genome-wide expression analyses: A pilot
study. Int J Geriatr Psychiatry, 31: 510–517. 61. ALFRED: The Allele Frequency Database. Available from:
https://doi.org/10.1002/gps.4356 https://alfred.med.yale.edu/alfred/index.asp [Last accessed
on 2023 Jan 02].
50. Murray CJ, 2022, The Global Burden of Disease Study at
30 years. Nat Med, 28: 2019–2026. 62. Bi M, Kang S, Du X, et al., 2020, Association between SNCA
rs356220 polymorphism and Parkinson’s disease: A meta-
https://doi.org/10.1038/s41591-022-01990-1 analysis. Neurosci Lett, 717: 134703.
51. Global Burden of Disease Study, 2019, (GBD 2019) Data https://doi.org/10.1016/j.neulet.2019.134703
Resources. Available from: https://ghdx.healthdata.org/gbd-
2019 [Last accessed on 2022 Dec 31]. 63. Magistrelli L, Contaldi E, Comi C, 2021, The impact of
SNCA variations and its product alpha-synuclein on non-
52. Akiskal HS, Bolis CL, Cazzullo C, et al., 1996, Dysthymia in motor features of Parkinson’s disease. Life, 11: 804.
neurological disorders. Mol Psychiatry, 1: 478–491.
https://doi.org/10.3390/life11080804
53. Han W, Liu Y, Mi Y, et al., 2015, Alpha-synuclein (SNCA)
polymorphisms and susceptibility to Parkinson’s disease: 64. Zhang Y, Shu L, Pan H, et al., 2018, A comprehensive analysis
of the association between SNCA polymorphisms and the
A meta-analysis. Am J Med Genet B Neuropsychiatr Genet, risk of Parkinson’s disease. Front Mol Neurosci, 11: 391.
168: 123–134.
https://doi.org/10.3389/fnmol.2018.00391
https://doi.org/10.1002/ajmg.b.32288
65. Heckman MG, Soto-Ortolaza AI, Diehl NN, et al., 2012,
54. Li C, Ou R, Chen Y, et al., 2021, Genetic modifiers of age Evaluation of the role of SNCA variants in survival without
at onset for Parkinson’s disease in Asians: A genome-wide neurological disease. PLoS One, 7: e42877.
association study. Mov Disord, 36: 2077–2084.
https://doi.org/10.1371/journal.pone.0042877
https://doi.org/10.1002/mds.28621
66. Biernacka JM, Armasu SM, Cunningham JM, et al., 2011,
55. Wang Q, Tian Q, Song X, et al., 2016, SNCA gene Do interactions between SNCA, MAPT, and LRRK2
polymorphism may contribute to an increased risk of genes contribute to Parkinson’s disease susceptibility?
Alzheimer’s disease. J Clin Lab Anal, 30: 1092–1099. Parkinsonism Relat Disord, 17: 730–736.
https://doi.org/10.1002/jcla.21986 https://doi.org/10.1016/j.parkreldis.2011.07.001

Volume 2 Issue 1 (2023) 12 https://doi.org/10.36922/an.326